Gastrointestinal peptides like CCK reduce meal size not through hardwired satiety mechanisms but because the brain has learned to associate them with caloric intake — and the body stops responding if the signal becomes unreliable.
Repeated peptide administration loses effectivenessWhen gut peptides like CCK are given repeatedly without actual caloric intake, the brain learns to ignore them — explaining why chronic treatment and genetic knockouts fail to produce lasting weight changes
What the researchers found
The review presents three key lines of evidence that gut peptide satiation is learned rather than innate. First, the ability of some GI peptides to modify food intake depends on past experience and can be changed with new experience (malleable). Second, CCK and other 'satiation' signals that reduce food intake acutely may not continue to do so over repeated trials. Third, individuals only respond to a particular signal so long as it provides reliable information about caloric content.
When a gut peptide becomes an unreliable predictor of calories (as happens with repeated exogenous administration), the individual shifts to relying on other signals to end meals. This learned association model explains why genetic knockouts and chronic peptide administration fail to produce sustained weight loss — the system compensates by using alternative satiety cues.
Why it matters
This review fundamentally challenges how we think about gut peptide-based obesity treatments. If CCK, GLP-1, and similar peptides work through learned associations rather than hardwired satiety circuits, it explains why chronic GLP-1 agonist treatment eventually plateaus and why weight regain occurs after discontinuation — the brain adapts. Understanding this could lead to more effective dosing strategies (perhaps intermittent rather than continuous) or combination approaches that prevent adaptive compensation.
How the study worked
This is a theoretical review synthesizing evidence from behavioral pharmacology, conditioning experiments, genetic knockout studies, and chronic peptide administration studies to propose a learning-based model of gut peptide satiation.
What this study cannot tell us
As a theoretical review, it presents a provocative hypothesis without definitive proof that all gut peptide satiation is learned. The evidence cited is largely from animal studies, and human learning mechanisms around food intake may be more complex. The model may overstate the role of learning and understate hardwired satiety mechanisms — GLP-1 drugs do produce sustained (if plateauing) weight loss for many patients, suggesting some non-learned component. The review also doesn't address the metabolic effects of gut peptides (glucose lowering, etc.) that contribute to their clinical value independent of appetite.
How to read the evidence
This is a theoretical review and perspective piece presenting a hypothesis about the mechanism of gut peptide satiation. While drawing on published experimental evidence, it does not present new data and the hypothesis remains debated in the field.
When this study was published
Published in 2018, this review predates the widespread clinical use of high-dose GLP-1 drugs for obesity but raises questions that are increasingly relevant as the weight loss plateau with these drugs becomes better documented.
The bigger picture
This perspective is particularly relevant in the GLP-1 drug era. Semaglutide and tirzepatide produce dramatic initial weight loss that plateaus after 12-18 months, and weight regain occurs upon discontinuation. The learned-association model proposed here offers an explanation: the brain may gradually learn that the pharmacological GLP-1 signal doesn't reliably predict the caloric content it once did, leading to compensatory increases in appetite through other pathways. This framework suggests that the current 'more peptide = more weight loss' approach may have inherent limits.
Questions still open
- Could intermittent dosing of GLP-1 drugs (rather than continuous weekly dosing) prevent the brain from learning to compensate, maintaining greater long-term effectiveness?
- Does the weight loss plateau observed with semaglutide and tirzepatide reflect the learned-association mechanism this review proposes?
- If gut peptide satiation is learned, could cognitive behavioral therapy enhance the effectiveness of peptide-based obesity treatments by reinforcing the peptide-calorie association?
Common questions
If gut hormones don't automatically make you feel full, what does?
Does this mean GLP-1 drugs like Ozempic will eventually stop working?
Read the original research
How and why do gastrointestinal peptides influence food intake?
Physiology & behavior, 193(Pt B), 218-222
Citation
Woods, Stephen C; May-Zhang, Aaron A; Begg, Denovan P. (2018). How and why do gastrointestinal peptides influence food intake?. Physiology & behavior, 193(Pt B), 218-222. https://doi.org/10.1016/j.physbeh.2018.02.048